Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation
A Phase II Study of Niraparib in Patients With Advanced Melanoma With Genetic Homologous Recombination (HR) Mutation / Alteration
Sponsor: California Pacific Medical Center Research Institute
This PHASE2 trial investigates Metastatic Melanoma and is currently ongoing. California Pacific Medical Center Research Institute leads this study, which shows 7 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Nov 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Nov 2021 — Nov 2023 [monthly]
Recruiting PHASE2
-
Jan 2021 — Nov 2021 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Jun 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
May 2019 — Jun 2020 [monthly]
Recruiting PHASE2
First recorded
Mar 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- California Pacific Medical Center Research Institute
- Huntsman Cancer Institute
- Tesaro, Inc.
- Vanderbilt-Ingram Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .